标题
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 4, Pages 3391
出版商
MDPI AG
发表日期
2023-02-09
DOI
10.3390/ijms24043391
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
- (2022) S Danese et al. Journal of Crohns & Colitis
- Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
- (2022) Diamant Thaçi et al. Dermatology and Therapy
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- New and Emerging Targeted Therapies for Hidradenitis Suppurativa
- (2022) Adela Markota Čagalj et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
- (2022) Christopher Tehlirian et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A Comprehensive Overview of Globally Approved JAK Inhibitors
- (2022) Ahmed M. Shawky et al. Pharmaceutics
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb , randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study
- (2022) Megan N. Landis et al. BRITISH JOURNAL OF DERMATOLOGY
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
- (2022) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- TYK2 in Immune Responses and Treatment of Psoriasis
- (2022) Lin Shang et al. Journal of Inflammation Research
- Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
- (2022) Iain B. McInnes et al. Rheumatology and Therapy
- Deucravacitinib: First Approval
- (2022) Sheridan M. Hoy DRUGS
- TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
- (2021) Christine E. Jo et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
- (2021) Silvio Danese et al. INFLAMMATORY BOWEL DISEASES
- Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
- (2021) James G. Krueger et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
- (2021) Anjaneya Chimalakonda et al. Dermatology and Therapy
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- (2021) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
- (2021) Ian M. Catlett et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- (2021) Elena Peeva et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
- (2021) Miguel Nogueira et al. Dermatology Practical & Conceptual
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
- (2020) Karen M. Page et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial
- (2020) Seth B. Forman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
- (2020) Brian S Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
- (2020) Ravi Shankar P. Singh et al. CTS-Clinical and Translational Science
- Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
- (2020) Chunjian Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
- (2019) Xingrui He et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
- (2019) Tamara Pérez-Jeldres et al. Frontiers in Pharmacology
- IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
- (2019) Wenjun Ouyang et al. IMMUNITY
- Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)
- (2019) Ryan Moslin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy
- (2015) Ankit Saxena et al. CYTOKINE
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
- (2014) Melissa G. Works et al. JOURNAL OF IMMUNOLOGY
- Mechanisms of Jak/STAT Signaling in Immunity and Disease
- (2014) Alejandro V. Villarino et al. JOURNAL OF IMMUNOLOGY
- Tyk2 is a therapeutic target for psoriasis-like skin inflammation
- (2013) M. Ishizaki et al. INTERNATIONAL IMMUNOLOGY
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- (2013) S. J. Sohn et al. JOURNAL OF IMMUNOLOGY
- The JAK/STAT Pathway
- (2012) D. A. Harrison Cold Spring Harbor Perspectives in Biology
- Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity
- (2011) Birgit Strobl Frontiers in Bioscience-Landmark
- IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice
- (2011) A. B. Van Belle et al. JOURNAL OF IMMUNOLOGY
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
- (2010) Amy Strange et al. NATURE GENETICS
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- A Single Nucleotide Polymorphism in Tyk2 Controls Susceptibility to Experimental Allergic Encephalomyelitis
- (2009) K. M. Spach et al. JOURNAL OF IMMUNOLOGY
- Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways
- (2008) Lin Jiang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now